Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia, Paliperidone palmitate, R092670, antipsychotic
Eligibility Criteria
Inclusion Criteria: Patients with a diagnosis of schizophrenia clinically stable with no change in current antipsychotic medications meet PANSS score criteria have a body mass index (BMI) between 15 and 35 kilogram (kg)/meter (m)2. Exclusion Criteria: Patients with DSM-IV diagnosis of alcohol or substance dependence, with the exception of nicotine or caffeine dependence involuntarily-committed have moderately severe or severe EPS symptoms history of malignant neuroleptic syndrome have current suicidal ideation or demonstrates violence current presence of any significant or unstable medication condition treatment with any protocol disallowed therapies clinically significant result from screening laboratory or ECG.